Related Articles
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
Long‑term survival of a <em>BRCA2</em> mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Hereditary breast and ovarian cancer susceptibility genes (Review)